Biontech expands global footprint by acquiring gmp manufacturing site to establish first mrna facility in singapore

Mainz, germany, and singapore, november 14, 2022 — biontech se (nasdaq: bntx, “biontech” or “the company”) today announced its singapore affiliate biontech pharmaceuticals asia pacific pte. ltd. had entered into an agreement with novartis singapore pharmaceutical manufacturing pte. ltd. to acquire one of its gmp-certified manufacturing facilities. the acquisition is part of biontech's expansion strategy to strengthen its global footprint in asia. supported by the singapore economic development board (“edb”), the facility will serve as biontech's regional headquarters and become its first mrna manufacturing facility in singapore.
BNTX Ratings Summary
BNTX Quant Ranking